Abstract:Structure-based drug design (SBDD) has gained popularity owing to its ability to develop more potent drugs compared to conventional drug-discovery methods. The success of SBDD relies heavily on obtaining the three-dimensional structures of drug targets. X-ray crystallography is the primary method used for solving structures and aiding the SBDD workflow; however, it is not suitable for all targets. With the resolution revolution, enabling routine high-resolution reconstruction of structures, cryogenic electron microscopy (cryo-EM) has emerged as a promising alternative and has attracted increasing attention in SBDD. Cryo-EM offers various advantages over X-ray crystallography and can potentially replace X-ray crystallography in SBDD. To fully utilize cryo-EM in drug discovery, understanding the strengths and weaknesses of this technique and noting the key advancements in the field are crucial. This review provides an overview of the general workflow of cryo-EM in SBDD and highlights technical innovations that enable its application in drug design. Furthermore, the most recent achievements in the cryo-EM methodology for drug discovery are discussed, demonstrating the potential of this technique for advancing drug development. By understanding the capabilities and advancements of cryo-EM, researchers can leverage the benefits of designing more effective drugs. This review concludes with a discussion of the future perspectives of cryo-EM-based SBDD, emphasizing the role of this technique in driving innovations in drug discovery and development. The integration of cryo-EM into the drug design process holds great promise for accelerating the discovery of new and improved therapeutic agents to combat various diseases.

Neutron crystallography aids in drug design

Drug design and synchrotron

Neutron Reflection and Scattering in Characterising Peptide Assemblies

Structure-based drug design: NMR-based approach for ligand-protein interactions.

High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design

Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery

3D electron diffraction for structure determination of small‐molecule nanocrystals: A possible breakthrough for the pharmaceutical industry

Exploring serial crystallography for drug discovery

Elucidation of a nutlin-derivative—HDM2 complex structure at the interaction site by NMR molecular replacement: A straightforward derivation

Protein X-ray Crystallography and Drug Discovery

Joint neutron crystallographic and NMR solution studies of Tyr residue ionization and hydrogen bonding: Implications for enzyme-mediated proton transfer

Crystal structure determination of Verinurad via proton-detected ultra-fast MAS NMR and machine learning

Structure-based drug design: From nucleic acid to membrane protein targets

NMR-guided refinement of crystal structures using 15N chemical shift tensors

X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?

Using X-Ray Crystallography to Simplify and Accelerate Biologics Drug Development

Neutron Macromolecular Crystallography for Biological Samples—Current State and Future Perspectives

Structure-based drug design: aiming for a perfect fit

Cryo-electron microscopy-based drug design

Drug discovery and optimization based on the co-crystal structure of natural product with target

GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures